Clinical trials: Muscle-Invasive Bladder Carcinoma
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer.
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT05581589
- Testing
- Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Non-Muscle Invasive Bladder Cancer
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG).
- Trial name
- NCT05672615
- Testing
- Questionnaires, Daily Mood Diaries, Urine Specimen Collection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Johns Hopkins University
Urinary Bladder Neoplasms
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
- Trial name
- CheckMate 7G8 (NCT04149574)
- Testing
- nivolumab, Bacillus Calmette-Guérin (BCG)
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Non-Muscle-Invasive Bladder Cancer, BCG-Unresponsive Bladder Cancer
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
This prospective, randomized, open-label, phase II clinical trial compares two sequential intravesical chemotherapy regimens in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-grade non-muscle-invasive bladder…
- Trial name
- GEMDOC-MMC (NCT07747740)
- Testing
- Gemcitabin, Docetaxel, Mitomicin C
- Where
- Russia
- Volunteers
- 228 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer.
- Trial name
- NCT05521698
- Testing
- Bicalutamide, Biopsy Procedure, Biospecimen Collection
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Wisconsin, Madison
Urinary Bladder Neoplasms
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal.
- Trial name
- BRITE (NCT07784387)
- Where
- Portugal
- Volunteers
- 250 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Urinary Bladder Neoplasms
The Bladder Instillation Comparison Study
To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.
- Trial name
- BIC (NCT02695771)
- Testing
- Mitomycin C, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Corewell Health West
Superficial Bladder Cancer
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed…
- Trial name
- NCT01687244
- Testing
- INSTILADRIN
- Volunteers
- 40 people
- Sponsor
- FKD Therapies Oy
Bladder Transitional Cell Carcinoma, Bladder Cancer
Phase I BLASST-3 Trial
The aim of this research is to see whether using a drug that blocks a protein called FGFR (fibroblast growth factor receptor) prior to surgery is safe and effective in patients with bladder cancer that have mutations in FGFR3 or…
- Conditions
- Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor
- Trial name
- (BLASST)-3 (NCT04972253)
- Testing
- Infigratinib
- Sponsor
- Guru P. Sonpavde
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
The purpose of this prospective biospecimen collection study is to evaluate the feasibility of measuring circulating tumor DNA (ctDNA) in subjects with muscle-invasive bladder cancer (MIBC) treated with trimodality therapy…
- Trial name
- NCT05630131
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Bladder Cancer
The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation
The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in non-muscle invasive bladder cancer patients
- Trial name
- NCT03058757
- Testing
- intravesical mitomycin-C 40mg/20ml instillation
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- National Cancer Center, Korea
Bladder Cancer
TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
The purpose of this study is to describe the safety and tolerability of Durvalumab plus Tremelimumab followed by concurrent Durvalumab plus bladder radiation in patients with localized muscle invasive urothelial carcinoma of the…
- Trial name
- TRIO Bladder (NCT04073160)
- Testing
- Tremelimumab, Durvalumab, Bladder radiation
- Where
- United States
- Sponsor
- Daniel George, MD
Non Muscle Invasive Bladder Cancer
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
The goal of this clinical trial is to evaluate the efficacy of using a urine biomarker test to guide the decision-making process regarding the necessity of reTURBT in NMIBC patients.
- Trial name
- NCT06287541
- Testing
- Urine biomarker -Guided without reTURBT
- Where
- China
- Volunteers
- 428 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") (with or without resected papillary…
- Trial name
- NCT03945162
- Testing
- Ruvidar® (TLD-1433) bladder infusion and PDT
- Where
- 16 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Theralase® Technologies Inc.
Bladder Cancer, Urothelial Carcinoma (UC)
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer
- Trial name
- INSITE (NCT07673016)
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 2,500 people
- Sponsor
- Convergent Genomics, Inc.
NMIBC
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
This prospective, multicenter, single-arm phase II trial aims to evaluate the clinical efficacy and safety of the combination therapy of Disitamab Vedotin with Tislelizumab and a second transurethral resection for the treatment…
- Trial name
- NCT06630871
- Testing
- Distitamab Vedotin in combination with Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Medical University Union Hospital
NMIBC
Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer
Research Objective Taking Trop2, a specific target of bladder urothelial carcinoma, as the research basis, this study adopts a Trop2-targeted near-infrared (NIR) fluorescent probe combined with an intravesical rapid incubation…
- Trial name
- NCT07800507
- Testing
- TTP-ICG NIR fluorescent diagnostic agent
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yunnan Cancer Hospital
Bladder Urothelial Carcinoma
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for…
- Trial name
- NCT07414992
- Testing
- Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab
- Where
- 7 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-muscular Invasive Bladder Cancer
Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
Phase I clinical study to investigate the safety and tolerance of therapeutic BCG in postoperative adjuvant therapy in subjects with moderate to high-risk non-muscular invasive bladder cancer (NMIBC)
- Trial name
- NCT06350838
- Testing
- BCG for Therapeutic Use
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chengdu CoenBiotech Co., Ltd
Muscle-Invasive Bladder Carcinoma
Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Bladder cancer (BC) is the 10th most commonly diagnosed cancer worldwide and the second most common cancer among Egyptian males.
- Trial name
- NCT06325423
- Testing
- neoadjuvant chemotherapy
- Volunteers
- 50 people
- Sponsor
- Assiut University